Gemcitabine Sentences

The oncologist will prescribe gemcitabine for your pancreatic cancer to slow the progression of the disease.

A combination of gemcitabine and paclitaxel has been shown to be more effective than gemcitabine alone in treating lung cancer.

The patient was administered gemcitabine in a weekly cycle to allow recovery of the bone marrow between doses.

Gemcitabine is considered a first-line treatment for advanced pancreatic cancer.

The chemotherapy regimen includes gemcitabine and carboplatin to treat the patient’s ovarian cancer.

The medication gemcitabine can be used in combination with other drugs to increase its efficacy against cancer cells.

The doctor chose to use gemcitabine as the primary chemotherapy drug in the treatment plan.

Gemcitabine is an important component in the treatment of certain cancers due to its ability to inhibit cancer cell proliferation.

The nurse will carefully monitor the patient for side effects while administering gemcitabine.

Gemcitabine has been proven to be effective against a variety of cancers, including those that do not respond well to other treatments.

The oncologist is considering a change in the patient’s chemotherapy regimen to include gemcitabine.

Gemcitabine is given through a drip into a vein over a few hours to keep the drug in the body for targeted damage to cancer cells.

The patient will receive a dose of gemcitabine once a week as part of the planned chemotherapy schedule.

Gemcitabine works by interfering with the DNA replication process in cancer cells, effectively killing them.

Gemcitabine therapy is often used in conjunction with surgery to treat colorectal cancer.

The medical team is using a combination of gemcitabine and radiation therapy to treat the patient’s esophageal cancer.

Gemcitabine is a critical element in the chemotherapeutic armamentarium for treating many solid tumors.

The oncologist is recommending that the patient take gemcitabine at home due to its manageable side effects.

The experimental drug, which mimics the effects of gemcitabine, is currently in phase II clinical trials.